97 related articles for article (PubMed ID: 8090750)
1. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
2. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
3. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
5. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Lando PA; Dohlsten M; Hedlund G; Akerblom E; Kalland T
Cancer Immunol Immunother; 1993; 36(4):223-8. PubMed ID: 8439985
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
7. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells.
Hedlund G; Dohlsten M; Petersson C; Kalland T
Cancer Immunol Immunother; 1993; 36(2):89-93. PubMed ID: 8425213
[TBL] [Abstract][Full Text] [Related]
8. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein.
Ma W; Yu H; Wang Q; Bao J; Yan J; Jin H
Cancer Immunol Immunother; 2004 Feb; 53(2):118-24. PubMed ID: 14574492
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.
Krupka HI; Segelke BW; Ulrich RG; Ringhofer S; Knapp M; Rupp B
Protein Sci; 2002 Mar; 11(3):642-51. PubMed ID: 11847286
[TBL] [Abstract][Full Text] [Related]
10. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
11. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells.
Ragnarsson L; Strömberg T; Wijdenes J; Tötterman TH; Weigelt C
Cancer Immunol Immunother; 2001 Sep; 50(7):382-90. PubMed ID: 11676398
[TBL] [Abstract][Full Text] [Related]
13. Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.
Zhao WB; Shen Y; Cai GX; Li YM; Liu WH; Wu JC; Xu YC; Chen SQ; Zhou Z
Mol Ther; 2024 Feb; 32(2):490-502. PubMed ID: 38098228
[TBL] [Abstract][Full Text] [Related]
14. Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.
Bashraheel SS; Goda SK
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445686
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-mediated inhibition of human T-cell acute lymphoblastic leukemia upon treatment with
Duarte A; Montagna DR; Pastorini M; Alemán M
Front Immunol; 2023; 14():1176432. PubMed ID: 37377961
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
17. Bidirectional Functional Effects of
Wei Y; Sandhu E; Yang X; Yang J; Ren Y; Gao X
Microorganisms; 2022 Nov; 10(12):. PubMed ID: 36557606
[TBL] [Abstract][Full Text] [Related]
18. Design of split superantigen fusion proteins for cancer immunotherapy.
Golob-Urbanc A; Rajčević U; Strmšek Ž; Jerala R
J Biol Chem; 2019 Apr; 294(16):6294-6305. PubMed ID: 30782846
[TBL] [Abstract][Full Text] [Related]
19. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
20. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.
Elkord E; Burt DJ; Sundstedt A; Nordle Ö; Hedlund G; Hawkins RE
Oncotarget; 2015 Feb; 6(6):4428-39. PubMed ID: 25669986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
